Cerebrolysin, Research Reference

Important note: Cerebrolysin is not a single peptide. It is a standardised mixture of low-molecular-weight neuropeptides and free amino acids derived from purified porcine (pig) brain protein. This distinction is fundamental to understanding how it is studied and how it differs from conventional synthetic research peptides.

The following protocol information is based on anecdotal community experience and publicly available research. It is not a medical recommendation. Dosages, frequencies, and routes described are reported ranges, not prescriptions. Individual responses vary. Use at your own risk.

Quick Reference

Overview

Cerebrolysin is a registered pharmaceutical product manufactured by EVER Neuro Pharma GmbH (Austria). It consists of a standardised aqueous solution of low-molecular-weight neuropeptides and free amino acids obtained through controlled enzymatic hydrolysis of purified porcine brain protein. The preparation is standardised to approximately 25% neuropeptide content by weight, with free amino acids comprising the remaining fraction.

Unlike the majority of research peptides documented on this site, Cerebrolysin is a complex biological mixture rather than a single synthetic molecule. This has implications for how it is studied, how its effects are attributed, and how it is regulated.

Because the active peptide fractions have molecular weights below 10,000 Da, they are considered small enough to cross the blood-brain barrier, which is proposed as a prerequisite for the neurotrophic and neuroprotective activity observed in research.

Research has investigated Cerebrolysin for a range of applications in neurology and cognitive medicine, including:

• Ischaemic stroke rehabilitation and recovery of neurological function
• Alzheimer’s disease and vascular dementia
• Traumatic brain injury (TBI) recovery
• Peripheral neuropathy
• Cognitive impairment in aging

Cerebrolysin holds regulatory approval in Russia, China, Austria, Germany, and numerous other European and Asian countries for the indications above. It is not approved by the United States Food and Drug Administration (FDA) and is classified as a research chemical in the United States.

Mechanism

The proposed mechanisms of action for Cerebrolysin are based on preclinical studies and on pharmacodynamic research conducted during clinical development. The peptide fractions within the mixture are reported to produce biological activity that resembles the effects of several endogenous neurotrophic factors.

Neurotrophic Factor-Like Activity

Research has proposed that the active peptide fractions mimic or potentiate the downstream signalling of:

• BDNF (brain-derived neurotrophic factor): associated with neuronal survival, synaptic plasticity, and long-term potentiation; one of the most studied targets in the context of dementia and cognitive decline
• NGF (nerve growth factor): involved in the maintenance and survival of cholinergic neurons in the basal forebrain, which are among the cell populations most affected in Alzheimer’s disease
• CNTF (ciliary neurotrophic factor): investigated for roles in motor neuron survival and neuroprotection against excitotoxic insult

The proposed action is not direct replacement of these factors but rather a pharmacomimetic effect on their downstream pathways. The peptide fractions are reported to bind to neurotrophin receptors and activate intracellular survival signalling cascades without being identical in structure to the endogenous proteins.

Blood-Brain Barrier Penetration

The low molecular weight of the active fractions (below 10,000 Da) is considered central to their proposed mechanism. Larger proteins such as BDNF itself do not readily cross the intact blood-brain barrier when administered peripherally. The small peptide fractions in Cerebrolysin are reported in the research literature to penetrate the CNS following parenteral administration, which is presented as a key pharmacokinetic advantage.

Neuroprotection and Anti-Excitotoxicity

Preclinical research has investigated the following proposed mechanisms:

• Reduction of oxidative stress in neuronal tissue
• Modulation of glutamate-mediated excitotoxicity, a pathway implicated in ischaemic injury and neurodegeneration
• Promotion of synaptogenesis and dendritic sprouting in models of neuronal injury
• Inhibition of apoptotic pathways in neurons exposed to ischaemic or traumatic insult
• Support of neuroplasticity, the capacity of surviving neuronal networks to reorganise following injury

Approved Indications

Cerebrolysin’s approved status varies substantially by jurisdiction. The following reflects countries where regulatory approval has been granted, and the indications for which it has been approved in clinical medicine.

Countries with Regulatory Approval

• Austria and Germany: Approved; marketed by EVER Neuro Pharma GmbH as the reference product
• Russia: Approved for stroke, dementia, TBI, and peripheral neuropathy; widely used in neurological clinical practice
• China: Approved; included in national stroke treatment guidelines in some versions
• Multiple Central and Eastern European countries: Approved for neurological indications; used in hospital settings for stroke rehabilitation and dementia management
• Several Asian and Latin American countries: Regulatory status varies; approved in a number of markets

Indications Where Approved

In jurisdictions where approval has been granted, Cerebrolysin is used in clinical medicine for:

• Ischaemic stroke: acute phase and rehabilitation, to support neurological recovery
• Alzheimer’s disease and vascular dementia: investigated for slowing cognitive decline and improving functional outcomes
• Traumatic brain injury: used in some hospital protocols for acute and post-acute care
• Peripheral neuropathy: reported in some approved labelling in specific jurisdictions

Research Chemical Status in the United States

Cerebrolysin is not approved by the FDA. In the United States it is classified as a research chemical. The clinical evidence base has been reviewed in the context of regulatory submissions, but no approval has been granted. Individuals in the United States should be aware of this distinction and verify applicable regulations.

Reported Protocols

The following information represents commonly reported research ranges drawn from clinical trial literature and anecdotal accounts. These are not medical recommendations.

Intravenous Infusion Protocol

Intravenous infusion is the most commonly reported route in clinical research and hospital practice. Cerebrolysin must NOT be administered as a rapid IV bolus. Slow infusion over 60 minutes is required. Rapid administration has been associated with adverse cardiovascular and autonomic effects.

Preparation for IV infusion:

• Cerebrolysin solution is diluted in 100 to 250 ml of normal saline (0.9% sodium chloride) immediately prior to administration
• The diluted solution is administered via slow intravenous infusion over approximately 60 minutes
• Do not mix with other medications or solutions other than normal saline unless directed by a qualified medical professional

Commonly reported doses in IV protocols:

• 10 ml IV: Commonly reported in moderate-intensity research protocols and in clinical practice for dementia and cognitive applications
• 20 ml IV: Commonly reported in more intensive protocols and in published stroke research
• 30 to 50 ml IV: Reported in higher-intensity stroke rehabilitation studies and in some published RCT protocols; the upper end of this range requires medical supervision

Commonly reported course duration:

• Courses of 10 to 20 consecutive daily infusions are the most commonly described in clinical and anecdotal accounts
• 1 to 3 courses per year are described in maintenance and rehabilitation contexts
• In acute stroke settings, daily infusions for 10 to 21 days are reported in the clinical trial literature

Intramuscular Protocol

Intramuscular injection is reported as an alternative to IV infusion, particularly for lower doses and outpatient or self-administration contexts in research settings.

• Commonly reported IM dose: 5 ml per injection, administered once daily
• Course duration: 10 to 20 days, consistent with IV course structures described above
• The gluteal muscle or lateral thigh is most commonly described as the injection site for IM administration
• Volumes above 5 ml per IM injection are not commonly reported, given the discomfort associated with larger IM volumes

Important Safety Note on Administration Rate

Cerebrolysin solution must not be injected rapidly. Intravenous infusion should be conducted slowly over a minimum of 60 minutes. Anecdotal reports and case literature describe adverse autonomic and cardiovascular reactions associated with rapid IV administration. This is a fundamental safety consideration in all reported protocols.

Reported Effects

The following effects have been reported in preclinical research, clinical trials, and anecdotal accounts. This list reflects the research landscape and does not constitute confirmed clinical outcomes for any specific individual.

Cognitive Function in Dementia Research

Research has most consistently investigated Cerebrolysin for cognitive outcomes in Alzheimer’s disease and vascular dementia. Published randomised controlled trials and meta-analyses have reported:

• Improvements in standardised cognitive assessment scores (MMSE, ADAS-Cog) compared to placebo in Alzheimer’s disease trials
• Reported improvements in activities of daily living and functional outcomes in some but not all trials reviewed
• Effects on vascular dementia have been investigated in separate trial programmes with broadly similar reported outcomes

The magnitude of cognitive benefit reported in the literature varies across studies, and some systematic reviews and Cochrane-adjacent meta-analyses have noted methodological heterogeneity and variable effect sizes across the trial base.

Stroke Recovery and Neurological Rehabilitation

Research has investigated Cerebrolysin in ischaemic stroke for both acute-phase neuroprotection and post-acute rehabilitation:

• Multiple RCTs have investigated 10 to 30 ml daily IV infusions commenced within days of ischaemic stroke onset
• Reported outcomes have included improved neurological function scores (NIHSS, Barthel Index) compared to placebo in some trials
• Research has proposed that the neuroprotective and synaptogenic effects of the peptide fractions contribute to improved neurological recovery

The evidence base for Cerebrolysin in stroke has been reviewed in several meta-analyses, with mixed conclusions regarding the robustness of the reported benefits, reflecting heterogeneity in trial design, dose, and timing of administration.

Traumatic Brain Injury

Anecdotal and clinical research has investigated Cerebrolysin in traumatic brain injury contexts. Reported observations include potential benefits in recovery of neurological function and cognitive outcomes following TBI. The evidence base in TBI is smaller than in stroke and dementia research and is considered preliminary.

Neuroplasticity Markers

Preclinical research has reported effects on markers associated with neuroplasticity, including dendritic sprouting, synaptogenesis, and the expression of neurotrophic factor signalling molecules, in animal models of neurodegeneration and ischaemic injury. Translational relevance to human clinical outcomes continues to be investigated.

Reported Side Effects

Reported side effects in research and anecdotal accounts include the following. This list does not constitute a comprehensive safety profile and should not be interpreted as predictive of individual outcomes.

Cerebrolysin is generally described as well-tolerated in the clinical trial literature at approved doses and administration rates. The most important safety consideration in reported protocols is adherence to the slow infusion requirement for IV administration. Rapid injection or bolus administration is not appropriate.

Contraindications reported in the literature:

• Known hypersensitivity to Cerebrolysin or to porcine-derived products
• Epilepsy (caution advised; some reports describe lowered seizure threshold in susceptible individuals, though evidence is limited)
• Severe renal failure (noted in some prescribing information)
• Pregnancy and breastfeeding (insufficient safety data; avoided in most clinical protocols)

Porcine origin note: Cerebrolysin is derived from porcine (pig) brain protein. This is relevant for individuals with dietary restrictions or religious observance that precludes contact with porcine-derived products.

Storage & Handling

Supplied Form

Cerebrolysin is supplied as a ready-to-use aqueous solution in glass ampules or vials, typically at concentrations of 215.2 mg/ml (equivalent to 1 ml Cerebrolysin containing the standardised neuropeptide fraction). It is not supplied as a lyophilized powder and does not require reconstitution before use. IV infusion preparations require dilution immediately before administration; IM doses are drawn directly from the ampule.

Ampule and Vial Storage

• Refrigerator (2-8°C): Preferred storage condition; consistently recommended to maintain solution stability and preserve activity of the peptide fractions
• Room temperature: Short-term storage at room temperature may be permissible according to some product labelling, but refrigeration is the consistently reported preferred condition
• Do not freeze: Freezing the aqueous solution is not appropriate and may affect the integrity of the peptide fractions
• Light sensitivity: Store in the original packaging or in an opaque container away from direct light exposure; glass ampules should not be exposed to prolonged direct sunlight

Pre-Administration Checks

• Inspect the solution visually before use; it should be clear and colourless to slightly yellowish
• Discard if the solution is cloudy, discoloured, or contains visible particulate matter
• Diluted IV infusion solutions should be prepared immediately before use and not stored after preparation

Frequently Asked Questions

Is Cerebrolysin a single peptide or a mixture? Cerebrolysin is not a single peptide. It is a standardised mixture of low-molecular-weight neuropeptides and free amino acids derived from purified porcine (pig) brain protein. The preparation is standardised to approximately 25% neuropeptide content by weight, with the remaining fraction consisting of free amino acids. The active peptide fractions have molecular weights below 10,000 Da, which enables them to cross the blood-brain barrier. Because the composition is a mixture rather than a single defined molecule, Cerebrolysin is sometimes classified separately from conventional synthetic peptides.

What is the regulatory status of Cerebrolysin? Cerebrolysin has received regulatory approval in Russia, China, Austria, Germany, and numerous other European and Asian countries, where it is approved for indications including ischaemic stroke rehabilitation, Alzheimer’s disease and other dementias, traumatic brain injury, and peripheral neuropathy. It is not approved by the United States Food and Drug Administration (FDA) and is classified as a research chemical in the United States. Regulatory status varies significantly by country; individuals should verify the applicable local regulations before acquisition or use.

What neurotrophic factors does Cerebrolysin mimic? The peptide fractions within Cerebrolysin have been reported in preclinical and clinical research to produce biological activity resembling that of several endogenous neurotrophic factors. Research has investigated similarities to brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), and ciliary neurotrophic factor (CNTF). The proposed mechanism is not direct replacement of these factors but rather a mimicry or potentiation of their downstream signalling pathways, contributing to reported effects on neuroprotection, synaptogenesis, neuroplasticity, dendritic sprouting, reduction of oxidative stress, and modulation of excitotoxicity.

How does Cerebrolysin compare to Semax and Selank? Cerebrolysin, Semax, and Selank are all investigated for cognitive and neuroprotective applications but differ substantially in composition and mechanism. Cerebrolysin is a complex porcine-derived neuropeptide mixture with neurotrophic factor-like activity and an approved pharmaceutical history in multiple countries. Semax is a synthetic heptapeptide analogue of ACTH(4-7) that has been reported to upregulate BDNF and is investigated primarily for cognitive enhancement and neuroprotection. Selank is a synthetic analogue of tuftsin with reported anxiolytic and nootropic properties, investigated in part for modulation of anxiety alongside cognitive function. The three compounds share overlapping goals in research contexts but operate through distinct mechanisms and have different evidence bases and regulatory histories.

Related Pages

Goals: Cognitive Support | Neuroprotection

Also see: Semax (synthetic ACTH analogue investigated for BDNF upregulation and cognitive applications), Selank (synthetic tuftsin analogue investigated for anxiolytic and cognitive properties), Dihexa (investigational compound studied for synaptogenic activity)

Comparisons: Semax vs Cerebrolysin

References & Further Reading

• Muresanu DF, et al. (2020). Cerebrolysin and recovery after stroke (CARS 2): a randomized, placebo-controlled, double-blind, multicenter trial. CNS Drugs, 34(12), 1271-1282. PubMed →
• Allegri RF, Guekht A. (2012). Cerebrolysin improves symptoms and delays progression in patients with Alzheimer’s disease and vascular dementia. Drugs of Today, 48(Suppl A), 25-41. PubMed →
• Wei ZH, et al. (2017). Cerebrolysin for vascular dementia. Neurological Sciences, 38(7), 1159-1166. Meta-analysis of randomised controlled trials. PubMed →
• Gauthier S, et al. (2015). Cerebrolysin in mild-to-moderate Alzheimer’s disease: a meta-analysis of randomized controlled clinical trials. Dementia and Geriatric Cognitive Disorders, 39(5-6), 332-347. PubMed →
• Chen CC, et al. (2013). Cerebrolysin for acute ischaemic stroke. Cochrane Database of Systematic Reviews. Cochrane →
• EVER Neuro Pharma GmbH. Cerebrolysin prescribing information and product monograph. EVER Neuro Pharma →